Search

Author/Creator Swinarski, D.

1. AB680, a potent and selective CD73 small molecule inhibitor, reverses the AMP/adenosine-mediated impairment of immune effector cell activation by immune checkpoint inhibitors. (March 2018)

Authors:
Schindler, U.; Becker, A.; Lawson, K.; Jin, L.; Jeffrey, J.; Kalisiak, J.; Yin, F.; Zhang, K.; Chen, A.; Swinarski, D.; Walters, M.J.; Young, S.; Powers, J.P.; Tan, J.
Journal:
European journal of cancer
Issue:
Volume 92(2018)Supplement 1
Page Start:
S14
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Discovery and characterization of potent and selective AXL receptor tyrosine kinase inhibitor AB801. (October 2022)

Authors:
Miles, D.; Paprcka, S.; Foley, C.; Qu, S.; Lamani, M.; Paladugu, S.; Huang, H.T.; Tibrewal, N.; Chen, A.; Kulusich, J.; Garrido-Shaqfeh, S.; Fabila, P.; Sridhar, S.; Liu, S.; Swinarski, D.; Zhao, X.; Fernandez-Salas, E.; Green, D.; Jin, L.; Leleti, M.
Journal:
European journal of cancer
Issue:
Volume 174(2022)Supplement 1
Page Start:
S103
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search